{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Memphis",
      "state": "TN",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "81943",
      "recalling_firm": "Rx Pak Division of McKesson Corporation",
      "address_1": "4971 Southridge Blvd Ste 111-115",
      "address_2": "N/A",
      "postal_code": "38141-8300",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Product was distributed to 5 major distributors who may have further distributed the product throughout the United States.",
      "recall_number": "D-1007-2019",
      "product_description": "Docusate Sodium, 100mg softgels, packaged in 10 x 10 unit dose blister cards, For institutional use only, Mfg by: Aenova Holding GmBh, Miami, Fl 33186, NDC 63739-0478-10",
      "product_quantity": "29,622 Blister Cards",
      "reason_for_recall": "Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate Sodium 100mg softgel caps.",
      "recall_initiation_date": "20190116",
      "center_classification_date": "20190315",
      "termination_date": "20201202",
      "report_date": "20190327",
      "code_info": "Lot # 0119397, Exp 02/2020"
    }
  ]
}